Fountain Biopharma Inc

Fountain Biopharma, established in December 2010 in Taiwan as a subsidiary of Microbio Co., Ltd., is dedicated to developing therapeutic monoclonal antibodies and DNA aptamers aimed at addressing unmet medical needs for cancer and immunological conditions through innovation. The company has implemented several pivotal platform technologies for novel drug development, including cancer stem cell culture technology, IgE platform technology, a fully human antibody library, high-throughput aptamer screening technology, high-yield cell line development, upstream/downstream manufacturing process development, analytical methods development, and an ILAC/TAF certified animal facility. Its pipelines and key technologies are bolstered through collaboration with several leading academic institutes. Fountain Biopharma has seven pipelines in various clinical and pre-clinical stages. Its global drug development strategy and strong positioning as a platform to enter Asia-Pacific markets make it an excellent partner in the development of antibody and aptamer therapeutics.

Fountain Biopharma operates in the Biotechnology, Health Care, and Pharmaceutical industries. With a founding date of 2010, the company is positioned as an innovative player in the development of therapeutics for challenging medical conditions.